The NIMML Institute and NImmune Biopharma have announced the publication of positive Phase 1 clinical results for NIM-1324, a first-in-class oral therapeutic for Systemic Lupus Erythematosus (SLE). The study, published in Clinical and Translational Science, demonstrated that NIM-1324 met all primary and secondary endpoints, confirming it as a safe and well-tolerated treatment with no dose-limiting toxicities. NIM-1324, a LANCL2 agonist, was developed to address the unmet medical need for safer and more effective SLE treatments, given the wide array of side effects associated with current drugs.
The clinical trial evaluated the safety and pharmacokinetics of NIM-1324 in healthy volunteers through single and multiple ascending doses in a blinded, placebo-controlled design. Results showed that NIM-1324 did not produce severe adverse effects or increase total adverse event rates compared to placebo. The study also reported dose-proportional changes in plasma exposure within the therapeutic range, with no accumulation during the dosing period. Furthermore, NIM-1324 was found to upregulate mitochondrial metabolism genes and downregulate markers of phagocyte activation, aligning with preclinical findings.
NIM-1324 activates the LANCL2 pathway, which modulates key cellular and molecular changes tied to inflammatory and autoimmune diseases. This activation increases the anti-inflammatory capacity of regulatory CD4+ T cells and supports the metabolic demands of autophagy in phagocytes. The therapeutic has shown promise in reducing interferon alpha production in SLE patients and providing protection from clinical disease and tissue pathology in mouse models of lupus and other autoimmune diseases.
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder that causes systemic inflammation and organ damage, affecting over 1.5 million patients in the United States and 5 million worldwide. The development of NIM-1324 represents a significant advancement in addressing the unmet medical need for safer and more effective SLE therapeutics.
The TITAN-X Precision Medicine Platform, developed by NIMML, played a crucial role in identifying NIM-1324 as a next-generation precision medicine. This A.I.-powered platform accelerates the development of precision medicines by integrating bioinformatics, computational modeling, and clinical data to identify responder patterns and tailor therapies to individual genetic signatures and clinical profiles.
